Please use this identifier to cite or link to this item: https://hdl.handle.net/11147/10124
Title: Targeting sphingosine kinase-1/spingosine-1-phosphate receptor 2 signalling pathway to overcome T315I mutation in 32DCL3 cells
Authors: Adan Gökbulut, Aysun
Öğretmen, Besim
Baran, Yusuf
Issue Date: 2014
Publisher: Elsevier Ltd.
Abstract: The main problem in chronic myeloid leukemia patients is the development of resistance against tyrosine kinase inhibitors. The expression of BCR-ABL1 having T315 mutation is responsible for the development of nilotinib resistance. The alterations in sphingolipid signalling pathway is a significant BCR-ABL1-dependent resistance mechanism. Recently, we showed that sphingosine kinase-1 (SK-1)/sphingosine-1 phosphate (S1P)-mediated drug resistance is transduced via sphingosine-1 phosphate receptor 2 (S1P2) that inhibits protein phosphatase 2A (PP2A), causing increased stability of BCR-ABL1. However, specific signaling cascade involved in this process remain unkown. In this study, BCR-ABL1 expressing 32Dcl3 cells, 32D-p210Bcr-Abl(wt) and 32D-p210Bcr-Abl (T315I) were used. The antiproliferative effects of nilotinib, SK-1 inhibitor (PF-543), S1P2 inhibitor (JTE-013), phospholipase C inhibitor (U-73122) and nilotinib/PF-543 and nilotinib/JTE-013 combinations on wt and resistant cells were determined by MTT assay. Isobologram analysis was performed using CompuSyn program.
Description: 5th International Eurasian Hematology Congress
URI: https://hdl.handle.net/11147/10124
ISSN: 0145-2126
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File SizeFormat 
1-s2.0-S0145212614701134-main.pdf76.07 kBAdobe PDFView/Open
Show full item record



CORE Recommender

Page view(s)

3,214
checked on Mar 4, 2024

Download(s)

172
checked on Mar 4, 2024

Google ScholarTM

Check





Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.